ArticleEuropean heart journal2025
The Australian-New Zealand spontaneous coronary artery dissection cohort study: predictors of major adverse cardiovascular events and recurrence.
Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Relief or Risk? Triptans, Migraines, and SCAD.JACC. Case reports · 2026Article
- Recurrent spontaneous coronary artery dissection, diagnostic issues, and management: a case report.European heart journal. Case reports · 2026Article
- Double Trouble: Clinical and Psychological Characteristics in SCAD With and Without Fibromuscular Dysplasia.JACC. Advances · 2026Article
- Acute coronary syndromes across the lifespan of women.NPJ cardiovascular health · 2026Review
- Spontaneous Coronary Artery Dissection: Advances in Understanding and Management in Women.Current atherosclerosis reports · 2026Review
- A Contemporary Review of Spontaneous Coronary Artery Dissection: CLINICAL CARE, CARDIAC REHABILITATION, AND FUTURE DIRECTIONS.Journal of cardiopulmonary rehabilitation and prevention · 2026Review
- Clinical Decision-Making and Imaging-Guided Follow-Up Strategies in Spontaneous Coronary Artery Dissection.Journal of cardiovascular development and disease · 2026Review
- Spontaneous Coronary Artery Dissection: Sex Differences in Clinical Presentation and Outcomes From the Australian New Zealand Registry.Journal of the American Heart Association · 2026Observational
- Spontaneous coronary artery dissection in an underrepresented region: insights from the Serbian (RS) SCAD registry.Frontiers in cardiovascular medicine · 2026Article
- Spontaneous coronary artery dissection as a threshold disorder of coronary wall integrity.Frontiers in cardiovascular medicine · 2026Review
- Case Report: Recurrent spontaneous coronary artery dissection involving the left main.Frontiers in cardiovascular medicine · 2026Article
- Article
- Shifting Paradigms in SCAD Care: Favoring OMT Over Intervention - Lessons from a National Cohort.Reviews in cardiovascular medicine · 2025Article
- Spontaneous Coronary Artery Dissection Clinical Review: Current State of Evidence and Challenges Ahead.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Review
- Article
- Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event.Current atherosclerosis reports · 2025Review
- Myocardial Infarction in Young Adults: A Case Series and Comprehensive Review of Molecular and Clinical Mechanisms.Biomolecules · 2025Review
- The Australian-New Zealand SCAD observational cohort study: major adverse cardiovascular events are associated with ticagrelor combined with aspirin, FMD, and history of stroke.European heart journal · 2025Article
- Myocardial Infarction in the Young: Aetiology, Emerging Risk Factors, and the Role of Novel Biomarkers.Journal of cardiovascular development and disease · 2025Review
- Spontaneous Coronary Artery Dissection: A Narrative Review of Epidemiology and Public Health Implications.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
BACKGROUND AND
aimsSpontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndrome (ACS). Recent data suggest a harmful association of dual antiplatelet therapy compared with single antiplatelet therapy following SCAD. This study investigated independent predictors of major adverse cardiovascular events (MACEs) and recurrence in patients with SCAD.
methodsThis multicentre cohort study involving 23 Australian and New Zealand sites included patients aged ≥18 years with an ACS due to SCAD confirmed on core laboratory adjudication. Multivariable Cox proportional hazard models analysed predictors for the primary MACE outcome.
resultsAmong 586 patients, 505 (150 prospective, 355 retrospective) with SCAD confirmed by core laboratory adjudication, mean age was 52.2 ± 10.6 years, 88.6% were female, and 74.5% were Caucasian. At long-term follow-up (median 21 months), MACE and SCAD recurrence occurred in 8.6% and 3.6% of patients, respectively. Oral anticoagulation on discharge [adjusted hazard ratio (aHR) 3.8, 95% confidence interval (CI) 1.6-9.3, P = .003], ticagrelor combined with aspirin (aHR 1.8, 95% CI 1.04-3.2, P = .037), fibromuscular dysplasia (aHR 2.2, 95% CI 1.05-4.5, P = .037), and history of stroke (aHR 3.8, 95% CI 1.2-12.2, P = .03) were independently associated with higher MACE. Fibromuscular dysplasia (aHR 3.9, 95% CI 1.5-26.5, P = .01), ticagrelor combined with aspirin (aHR 2.6, 95% CI 2.1-5.3, P = .01), and history of stroke (aHR 6.2, 95% CI 1.8-9.5, P = .01) were also associated with higher SCAD recurrence.
conclusionsThe findings support the hypothesis that SCAD is primarily caused by intramural bleeding, with a harmful association of more potent antiplatelet therapy and anticoagulation with adverse cardiovascular outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.